[go: up one dir, main page]

MX2018004220A - Tetrahidropiranilsulfonas sustituidas con pirazolilo. - Google Patents

Tetrahidropiranilsulfonas sustituidas con pirazolilo.

Info

Publication number
MX2018004220A
MX2018004220A MX2018004220A MX2018004220A MX2018004220A MX 2018004220 A MX2018004220 A MX 2018004220A MX 2018004220 A MX2018004220 A MX 2018004220A MX 2018004220 A MX2018004220 A MX 2018004220A MX 2018004220 A MX2018004220 A MX 2018004220A
Authority
MX
Mexico
Prior art keywords
pyrazolyl substituted
tetrahydropyranylsulfones
compounds
substituted tetrahydropyranylsulfones
pyrazolyl
Prior art date
Application number
MX2018004220A
Other languages
English (en)
Inventor
Reich Melanie
Michael Koenigs René
Scnk Stefan
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2018004220A publication Critical patent/MX2018004220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a tetrahidropiranilsulfonas sustituidas con pirazolilo como bloqueadores de los canales de calcio dependientes de voltaje, a composiciones farmacéuticas que contienen estos compuestos y también a estos compuestos para utilizar en el tratamiento y/o profilaxis del dolor y de otras enfermedades y/o trastornos.
MX2018004220A 2015-10-08 2016-10-07 Tetrahidropiranilsulfonas sustituidas con pirazolilo. MX2018004220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15002879 2015-10-08
PCT/EP2016/025107 WO2017059965A1 (en) 2015-10-08 2016-10-07 Pyrazolyl substituted tetrahydropyranylsulfones

Publications (1)

Publication Number Publication Date
MX2018004220A true MX2018004220A (es) 2018-11-09

Family

ID=54293014

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004220A MX2018004220A (es) 2015-10-08 2016-10-07 Tetrahidropiranilsulfonas sustituidas con pirazolilo.

Country Status (12)

Country Link
US (1) US10106530B2 (es)
EP (2) EP3359534A1 (es)
JP (1) JP2018530567A (es)
CN (1) CN108368092A (es)
AR (1) AR106296A1 (es)
AU (1) AU2016336776A1 (es)
BR (1) BR112018007006A2 (es)
CA (1) CA3001044A1 (es)
HK (1) HK1258456A1 (es)
MX (1) MX2018004220A (es)
TW (1) TW201718557A (es)
WO (1) WO2017059965A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016013451A (es) 2014-04-14 2017-01-18 Gruenenthal Gmbh Heterociclilsulfonas arilo sustituidas.
AR100073A1 (es) 2014-04-14 2016-09-07 Gruenenthal Gmbh Sulfonas heterocíclicas sustituidas con heteroarilos
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸
MX2020001352A (es) 2017-08-09 2020-03-20 Denali Therapeutics Inc Compuestos, composiciones y metodos.
EP3676297B1 (en) * 2017-09-01 2023-05-17 Denali Therapeutics Inc. Compounds, compositions and methods
EP3923935A4 (en) 2019-02-13 2022-10-26 Denali Therapeutics Inc. COMPOUNDS, COMPOSITIONS AND METHODS
MA54959A (fr) 2019-02-13 2021-12-22 Denali Therapeutics Inc Composés, compositions et procédés
WO2021038586A1 (en) * 2019-08-29 2021-03-04 Keminntek Laboratories Improved process for the preparation of tezacaftor intermediate

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589116B2 (en) * 2003-04-03 2009-09-15 Merck & Co. Inc. Biaryl substituted pyrazoles as sodium channel blockers
TW200740803A (en) * 2005-12-21 2007-11-01 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
WO2007125398A2 (en) * 2006-04-27 2007-11-08 Pfizer Japan Inc. : sulfonamide compounds as antagonists of the n-type calcium channel
AU2008256937A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
NZ598269A (en) 2009-09-18 2014-12-24 Zalicus Pharmaceuticals Ltd Aryl sulphone derivatives as calcium channel blockers
CA2882038A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
KR20150042834A (ko) * 2012-08-16 2015-04-21 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피라졸
TW201416348A (zh) * 2012-08-29 2014-05-01 Gruenenthal Chemie 以氟甲基取代之吡咯甲醯胺
MX2016013451A (es) * 2014-04-14 2017-01-18 Gruenenthal Gmbh Heterociclilsulfonas arilo sustituidas.
AR100073A1 (es) 2014-04-14 2016-09-07 Gruenenthal Gmbh Sulfonas heterocíclicas sustituidas con heteroarilos
TW201726128A (zh) 2015-10-08 2017-08-01 歌林達有限公司 經吡唑基取代之四氫哌喃基碸

Also Published As

Publication number Publication date
JP2018530567A (ja) 2018-10-18
CA3001044A1 (en) 2017-04-13
HK1258456A1 (zh) 2019-11-15
US20170101397A1 (en) 2017-04-13
TW201718557A (zh) 2017-06-01
WO2017059965A1 (en) 2017-04-13
EP3617203A1 (en) 2020-03-04
BR112018007006A2 (pt) 2018-10-16
AR106296A1 (es) 2018-01-03
EP3359534A1 (en) 2018-08-15
CN108368092A (zh) 2018-08-03
US10106530B2 (en) 2018-10-23
AU2016336776A1 (en) 2018-05-24

Similar Documents

Publication Publication Date Title
MX2016013447A (es) Heterociclilsulfonas heteroarilo sustituidas.
MX2018004220A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
MX2018006223A (es) Moduladores de ror-gamma.
MX2017005834A (es) Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MY191337A (en) Compositions for the treatment of hypertension and/or fibrosis
MX2018004217A (es) Tetrahidropiranilsulfonas sustituidas con pirazolilo.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2016007955A (es) Pirrol carboxamidas iii fluorometil-sustituidas.
MX2017013772A (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.
MX2016013451A (es) Heterociclilsulfonas arilo sustituidas.
PH12018500886A1 (en) Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2016007951A (es) Pirrol carboxamidas iv fluorometil-sustituidas.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2016007956A (es) Pirrol carboxamidas fluorometil-sustituidas como bloqueadores del canal de calcio de cav2.2.
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
GB2553686A8 (en) Ethynylxanthines, preparation and use as calcium ion channel modulators
TR201716203A1 (tr) Yeni umeklidinyum formülasyonları.